ProShare Advisors
GEVA

ProShare Advisors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

ProShare Advisors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-34,261
Closed -$3.34M – 1904
2015
Q1 		$3.34M Buy
34,261
+7,668
+29% +$812K 0.04% 407
2014
Q4 		$2.47M Buy
26,593
+1,005
+4% +$79.3K 0.03% 510
2014
Q3 		$1.76M Sell
25,588
-4,884
-16% -$350K 0.02% 792
2014
Q2 		$3.19M Sell
30,472
-12,497
-29% -$1.06M 0.04% 471
2014
Q1 		$3.56M Buy
42,969
+28,058
+188% +$2.59M 0.04% 404
2013
Q4 		$965K Sell
14,911
-5,532
-27% -$328K 0.01% 988
2013
Q3 		$1.29M Buy
20,443
+7,919
+63% +$390K 0.03% 676
2013
Q2 		$526K Buy
+12,524
New +$571K 0.01% 1301

ProShare Advisors's GEVA Position: Q2 2015 in Review

ProShare Advisors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 34,261 shares — an estimated $3.34M sold.

ProShare Advisors first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $3.56M in Q1 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • ProShare Advisors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • ProShare Advisors sold 34,261 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $3.34M.
  • ProShare Advisors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • ProShare Advisors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $3.56M in Q1 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on ProShare Advisors's 13F filing for Q2 2015, filed 11 Aug 2015.